Filing Flows › Zevra Therapeutics (ZVRA) › Q1 2026
Zevra Therapeutics (ZVRA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Zevra Therapeutics (ZVRA) reported revenue of $36.2M for the first quarter 2026 (Q1 2026), +78% from a year earlier and +6% from the quarter before. Operating margin was 144.0%, net earnings $37.9M (104.6% of revenue).
Zevra Therapeutics, Q1 2026: revenue $36.2M (+78% year over year), operating margin 144.0%, net earnings $37.9M, operating cash flow $6.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $36.2M | +6% | +78% |
| Operating profit | $52.1M | +460% | — |
| Net earnings | $37.9M | +211% | — |
| Operating cash flow | $6.1M | +11% | — |
| Free cash flow | $6.1M | +10% | — |
What changed
Revenue was $36.2M in Q1 2026, up 78% year over year and up 6% from the previous quarter.
Operating profit was $52.1M, a 144.0% margin (up 170.3 points year over year). Net earnings were $37.9M. The effective tax rate was 15.4%.
Operating cash flow was $6.1M, 16% of net earnings. Non-cash charges added back $368K of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items used $35.2M. Capital expenditures of $35K left free cash flow of $6.1M.
Questions
What was Zevra Therapeutics' revenue in the first quarter 2026?
Zevra Therapeutics (ZVRA) reported revenue of $36.2M for the first quarter 2026 (Q1 2026), +78% from a year earlier and +6% from the quarter before.
Was Zevra Therapeutics profitable in the first quarter 2026?
Operating profit was $52.1M (144.0% of revenue) and net earnings $37.9M.
Source: Zevra Therapeutics 10-Q on SEC EDGAR.